ATLASATLAS fair value
€43.63
Close to fair value · 3% premium
Range: €35–€78Fair valuePrice
QIAGEN (QIA.XETRA)
QIAGEN stock price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · Xetra (Deutsche Börse) · Germany
€45.09▲ +0.09%
Prices as of Oct 30, 2026 · EUR
Chance of rising in 1 month
51%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on QIAGEN in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On QIAGEN
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates QIAGEN's fair value at about €43.63 per share (reasonable range: €34.68 to €78.33). At €45.09, the stock trades within 8% of that figure: close to fair value.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is high. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives QIAGEN a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between €43.06 and €47.46; in 9 out of 10, between €39.50 and €51.73. Estimated annual volatility is 29%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- €9.3B
- Market cap (USD)
- $10.4B
- P/E ratio
- 26.7
- Dividend yield
- 0.81%
- 52-week high
- €47.59
- 52-week low
- €27.56
- Revenue (12 months)
- $2.1B
- Gross margin
- 66.4%
- Operating margin
- 26.3%
- Net margin
- 19.5%
- Beta
- 0.61
How QIAGEN compares
Against the Healthcare sector
At a P/E ratio of 26.7, QIAGEN is valued above the sector median of 22.6.
| Measure | QIAGEN | Sector median |
|---|---|---|
| P/E ratio | 26.7 | 22.6 |
| Net margin | 19.5% | 6.0% |
| Price vs fair value (+ above, − below) | +3% | -11% |
Median of the 25 Healthcare companies ATLAS covers (Germany). QIAGEN ranks #8 of 25 by market value among them.
QIAGEN stock performance over the past year
QIAGEN shares rose 10.6% between the Oct 31, 2025 close (€40.76) and the Oct 30, 2026 close (€45.09). Weekly closes over the period ranged from €28.11 to €46.13. Past performance does not predict future results.
QIAGEN compared with peers
Key numbers for QIA.XETRA next to comparable companies in the same line of business.
| Company | Market cap | P/E | Net margin | Price vs fair value |
|---|---|---|---|---|
| QIAGEN (QIA.XETRA) | $10.4B | 26.7 | 19.5% | +3% |
| Fresenius Medical Care AG & Co. (FME.XETRA) | $11.7B | 11.9 | 4.8% | – |
| Sartorius (SRT.XETRA) | $15.9B | 78.5 | 6.0% | +117% |
| Sartorius (SRT3.XETRA) | $19.9B | 102.2 | 6.0% | +183% |
| SCHOTT Pharma AG & Co. (1SXP.XETRA) | $4.1B | 28.1 | 13.4% | +31% |
Price vs fair value: + means the price is above the ATLAS fair value estimate, − below it. Market cap in US dollars.
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. QIAGEN sits close to fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks QIA.XETRA has traded between €27.56 and €47.59. Today it is 5.3% below that high and 64% above its low.
On the business: net margin is 19.5%; it trades at 26.7 times earnings.
Its beta is 0.61: it tends to move less than the market.
About the company
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Want to see everything about QIAGEN?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is QIAGEN (QIA.XETRA) fair value?
About €43.63 per share according to ATLAS (reasonable range: €34.68 to €78.33). With the stock at €45.09, it is close to that value.
What is the chance QIA.XETRA goes up next month?
51%: close to a coin flip. In half of the simulated outcomes, QIA.XETRA ends the month between €43.06 and €47.46.
How big is QIAGEN and what is its P/E ratio?
QIAGEN's market capitalization is €9.3B. Its price-to-earnings (P/E) ratio is 26.7: you pay €26.7 for each €1.00 of yearly earnings.
Does QIAGEN pay a dividend?
Yes. QIA.XETRA's current dividend yield is 0.81% at today's price (€45.09).
How has QIA.XETRA stock performed over the past year?
QIAGEN shares rose 10.6% between the Oct 31, 2025 close (€40.76) and the Oct 30, 2026 close (€45.09). Weekly closes over the period ranged from €28.11 to €46.13. Past performance does not predict future results.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer